Longevica raises about 280 million yen to launch open research resources useful for life-extending research | Today Nation News

TechnologyLongevica raises about 280 million yen to launch open...

Life sciences company Longevica announced on November 24, local time, that it will launch an open research tool. Give drug testing scientists and research institutes access to datasets that track the effects of over 1000 pharmacological compounds.

This is the latest initiative of the biotechnology company. The company raised $ 2.5 million in a round led by Xploration Capital to study healthy aging and lifespan extension mechanisms.

In April, Longevica announced a lineup of supplements based on research results. The company started over 11 years ago and now has more than $ 15.5 million from investors, including longevity investor and company president Alexander Chikunov. Procured.

Related article: Longevity startup Longevica plans to launch supplements based on long-term research

Longevica co-founder and CEO Ainar Abdrakhmanov emailed TechCrunch to find the best way to harness research results as soon as possible when they’re out of stealth, and products for consumers. He said he was focusing on getting some of them to market.

“But through a series of in-depth interviews, we found that most scientists in the field of longevity lacked infrastructure. We used an in-house engine to leverage much of the research through our partnership. We decided to share it, providing researchers with the data infrastructure they need to do their jobs, “added Abdullakmanov.

Living long is an area that other companies are working on for both humans and pets. The global anti-aging drug market is projected to reach approximately $ 8 billion in 2020 and double in 2027.

Meanwhile, Crunchbase News surveyed the status of longevity startups in July and found that more than 30 companies operating in this area have raised billions of dollars (hundreds of billions of yen) in total. I found out that there was. A recent example is Loyal, which has raised $ 27 million. The company has a long-term vision of investigating the longevity of animals and linking it to the longevity of humans.

READ MORE  Dramatic, Hafiz/Gloria Reach the Quarter Finals of the Indonesia Open 2021 after Defeating the Japanese Pair

Longevica started raising money when it came up with the idea of ​​an end-to-end open research platform. The funds raised this time will be used to support the development of the platform and the integration of the company’s research datasets.

Abdullah Manov says the goal is to validate the pipeline that makes scientific research a consumer-friendly product.

“There are many hypotheses about aging and longevity, but actually testing those hypotheses to determine who is right is clearly the bottleneck,” he added. “Our platform should help the scientific community get a little closer to the answer.”

An initial study led by Chikunov and Longevica co-founder Dr. Alexey Ryazanov tested 1033 compounds and showed significant life-extending effects. A peer-reviewed paper is about to be published for that study. Abdullah Manov says this is a “rather moonshot project.” The company’s investors have found that this direction will lead to faster results and benefit the industry as a whole.

With new research capabilities, Longevica will test 300 compounds more deeply in a new study at Jackson Laboratory. In January 2022, we will start accepting applications from researchers who want to try the drug in a full-scale pharmacological screening experiment that will start in June.

“Also in January, we will launch a public database, including markup data for most longevity-related experiments with mice, both public and unpublished,” Abdullah Manov said. Mr. speaks. “The platform is all free and open source, and the program code is also published on GitHub.”

Image Credit: Vinoth Chandar

[To the original text]

(Sentence: Christine Hall, Translation:saurabh


Latest news

You might also likeRELATED
Recommended to you